4//SEC Filing
Kerstein David 4
Accession 0001104659-23-027625
CIK 0001745020other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 7:01 AM ET
Size
5.7 KB
Accession
0001104659-23-027625
Insider Transaction Report
Form 4
Kerstein David
Chief Medical Officer
Transactions
- Award
Restricted Stock Units
2023-03-01+17,500→ 17,500 total→ Common Stock (17,500 underlying)
Footnotes (2)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
- [F2]The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date.
Documents
Issuer
Theseus Pharmaceuticals, Inc.
CIK 0001745020
Entity typeother
Related Parties
1- filerCIK 0001796388
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 7:01 AM ET
- Size
- 5.7 KB